Konjenital hipogonadotropik hipogonadizm hastalarında testosteron replasman tedavisinin inflamasyon ve insülin direncine etkisi

Cardio-metabolic risk is increased in hypogonadism. The effect of testosterone replacement treatment (TRT) on the cardiovascular and metabolic outcomes in hypogonadal patients is not clear. We investigated the effect of TRT on the insulin resistance and inflammation in patients with congenital hypogonadotrophic hypogonadism (CHH). A total of 80 patients with CHH (mean age 21,5±2,13 years) were enrolled. TRT was implemented in injectable and transdermal form. The demographic parameters, Pentraxin-3 (PTX3), high sensitive C reactive protein (hs-CRP) and homeostatic model assessment of insulin resistance (HOMA-IR) levels were measured before and after TRT. After 6,0±2.41 months of TRT, body mass indexes (p